INTRA-CELLULAR THERAPIES, INC.
430 East 29th Street
New York, New York 10016
September 10, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jeffrey Gabor
| RE: | Intra-Cellular Therapies, Inc. |
Registration Statement on Form S-3
Filed August 30, 2019
File No. 333-233537
Acceleration Request
Dear Mr. Gabor:
With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Intra-Cellular Therapies, Inc. (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Thursday, September 12, 2019, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call John Condon of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions regarding the Registration Statement.
| Very truly yours, |
| INTRA-CELLULAR THERAPIES, INC. |
| /s/ Michael I. Halstead |
| Michael I. Halstead |
| Executive Vice President, General Counsel and Secretary |
| cc: | William C. Hicks, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
John P. Condon, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.